APVO_OUT_1 [2025-04-02 14:45:15 -0400] 3162 Bytes | 837 tokens | Cum: 837 tkns (10.46% of 8k)
==========================================================================

We need a winner today and it's already 2:45:15 PM on Wed Apr 02, 2025 -0400 ... So let's find out if Aptevo Therapeutics (APVO) is going up or if it's going nowhere fast. So, I pulled together a bunch of data for you to look over real fast. It's at 2 up from 0.9981. Is there something here we can get excited about? Help me analyze.

--- COMPANY PROFILE ---
Company: Aptevo Therapeutics (APVO)
IPO: 2016-07-20 (8 Years Ago)
Market Cap: $1,483,968
Shares Outstanding: 1,460,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Here's the first list of news for Aptevo Therapeutics:

C1 - Mar-20-25 02:26PM - Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment
C2 - Mar-20-25 02:26PM 08:35AM - RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment
C3 - Mar-18-25 08:05AM - Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy
C4 - Mar-06-25 08:00AM - Aptevo to Participate in March Conferences
C5 - Feb-15-25 06:59PM - Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
C6 - Feb-14-25 08:05AM - Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update
C7 - Jan-15-25 08:00AM - Aptevo's Peter Pavlik, PhD, Chairing Session on 'Bi and Multispecific Biologics' at Cambridge Healthcare Institute's Pep Talk 2025
C8 - Dec-12-24 12:50PM - Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Aptevo Therapeutics (APVO)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

APVO_OUT_3 [2025-04-02 14:45:22 -0400] 1100 Bytes | 296 tokens | Cum: 1135 tkns (14.19% of 8k)
==========================================================================

Showing C1 (chunk 1 of 4): C1:
**Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment**
Date: Mar-20-25 02:26PM
Source: (Benzinga)
URL: https://finance.yahoo.com/news/aptevo-therapeutics-says-two-additional-182635823.html

On Thursday,Aptevo Therapeutics(NASDAQ:APVO) announced two additional frontline Acute Myeloid Leukemia (AML) patients have achieved remission within 30 days of treatment in the RAINIER dose optimization trial of mipletamig in combination with standard of care for patientsunfit for intensive chemotherapy.

9 of 10 frontline patients across two trials achieved remission when receiving the triplet combination of mipletamig + venetoclax +azacitidine (ven/aza).

Notably, no cytokine release syndrome (CRS) has been reported in the RAINIER trial to date.

Also Read:What’s Going On With Aptevo Therapeutics Shares Friday?

The data b

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

APVO_OUT_5 [2025-04-02 14:45:23 -0400] 969 Bytes | 285 tokens | Cum: 1530 tkns (19.12% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-01T17:06:07Z - APVO stock plunges to 52-week low, touches $0.99 By Investing.com...
A2 - 2025-04-01T17:05:13Z - APVO stock plunges to 52-week low, touches $0.99 By Investing.com...
A3 - 2025-03-20T18:26:35Z - Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Wit...
A4 - 2025-03-20T18:26:35Z - Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Wit...
A5 - 2025-03-20T12:53:22Z - RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

APVO_OUT_7 [2025-04-02 14:45:27 -0400] 1098 Bytes | 300 tokens | Cum: 1832 tkns (22.90% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**APVO stock plunges to 52-week low, touches $0.99 By Investing.com**Date: 2025-04-01Source: {'uri': 'uk.investing.com', 'dataType': 'news', 'title': 'Investing.com UK'}URL: https://uk.investing.com/news/company-news/apvo-stock-plunges-to-52week-low-touches-099-93CH-4008946Aptevo Therapeutics Inc (NASDAQ:APVO) stock has hit a distressing milestone, tumbling to a 52-week low of $0.99, with the company's market capitalization shrinking to just $1.46 million. According to InvestingPro data, technical indicators suggest the stock is in oversold territory. This significant drop reflects a stark downturn for the biotechnology firm, which has seen its market value erode over the past year. Investors have witnessed a precipitous decline, with the 1-year change data revealing a staggering -99.31% fall from previous levels. Despite the current price being well below the analyst target of $21,

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

APVO_OUT_9 [2025-04-02 14:45:28 -0400] 863 Bytes | 293 tokens | Cum: 2237 tkns (27.96% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-07-17T10:03:31Z - Why Bloom Energy Group Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Benzinga
B2 - 2024-05-28T12:19:00Z - Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
B3 - 2024-04-24T10:31:00Z - Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
B4 - 2024-04-16T16:47:00Z - Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why
B5 - 2024-04-11T19:21:09Z - Nasdaq Jumps 250 Points; Crude Oil Down 1%
B6 - 2024-04-11T17:33:07Z - Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

APVO_OUT_11 [2025-04-02 14:45:31 -0400] 629 Bytes | 189 tokens | Cum: 2428 tkns (30.35% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E**Date: Unknown DateSource: Unknown SourceURL: https://www.zacks.com/stock/news/2260816/why-you-should-bet-on-5-top-ranked-stocks-with-rising-peTap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Groupon (GRPN), Aptevo Therapeutics (APVO), NewJersey Resources (NJR), American Water Works (AWK) and Frontdoor (FTDR).

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

APVO_OUT_13 [2025-04-02 14:45:32 -0400] 1070 Bytes | 291 tokens | Cum: 2783 tkns (34.79% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S5 - 2025-02-14 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following Mgts Discussion and Analysis of Fin Cond and Results of Oper (this MDA) together with the CONS financial statements and t...

S6 - 2025-02-14 8-K Item 2.02 Results of Oper and Fin Cond.

On February 14, 2025, Aptevo Therapeutics Inc. (the Company) issued a press release announcing its financial results for the period ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 a...

S7 - 2024-12-12 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On December 12, 2024, Aptevo Therapeutics Inc. (the Company) entered into a warrant inducement agreement (the Inducement Agrmt) with certain holders (the Holders) of the Companys Series A common stock purchase warrants, ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

APVO_OUT_15 [2025-04-02 14:45:32 -0400] 1098 Bytes | 235 tokens | Cum: 3020 tkns (37.75% of 8k)
==========================================================================

Showing S5 (chunk 1 of 6): S5:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following Managements Discussion and Analysis of Financial Condition and Results of Operations (this MDA) together with the consolidated financial statements and the related notes thereto included in this Annual Report on Form 10-K. This MDA contains forward-looking statements that are subject to risks and uncertainties, such as those set forth in the sections of this Annual Report on Form 10-K captioned Cautionary Note Regarding Forward-Looking Statements, Risk Factors and elsewhere. As a result, our actual results may differ materially from those anticipated in these forward-looking statements.

Overview

We are a clinical-stage, research and development biotechnology company focused on developing novel immunotherapy candidates for the treatment of different forms o

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

APVO_OUT_17 [2025-04-02 14:45:42 -0400] 5096 Bytes | 1518 tokens | Cum: 4540 tkns (56.75% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+-----------------------+-----------------------+
| Volume: 15,884,058 | Perf Month: -49.15% | Option/Short: No / No | Sales Y/Y TTM: - |
+--------------------+-----------------------+-----------------------+-----------------------+
| Avg Volume: 65.64K | Perf Quarter: -68.62% | Short Float: 8.26% | ROE: -284.28% |
+--------------------+-----------------------+-----------------------+-----------------------+
| Rel Volume: 310.88 | Index: - | Short Ratio: 1.84 | ROI: -257.14% |
+--------------------+-----------------------+-----------------------+-----------------------+
| RSI (14): 34.12 | Market Cap: 2.19M | Short Interest: 0.12M | Sales Surprise: - |
+--------------------+-----------------------+-----------------------+-----------------------+
| ATR (14): 0.48 | Shs Outstand: 1.46M | Beta: 6.00 | EPS Surprise: -15.35% |
+--------------------+-----------------------+-----------------------+-----------------------+
| SMA20: -28.92% | Shs Float: 1.46M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+-----------------------+-----------------------+
| SMA50: -52.25% | Inst Own: 3.33% | Sales past 5Y: 2.12% | Earnings: Feb 14 BMO |
+--------------------+-----------------------+-----------------------+-----------------------+
| SMA200: -82.79% | Insider Own: 0.01% | Employees: 42 | |
+--------------------+-----------------------+-----------------------+-----------------------+
| Perf Week: -2.60% | Insider Trans: 0.00% | Debt/Eq: 0.97 | |
+--------------------+-----------------------+-----------------------+-----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Aptevo Therapeutics Inc. (APVO) by Taylor Daphne (SVP, CFO) on 2025-03-02
- Common Stock: 2 shares at $N/A (D)
- Common Stock: 1 shares at $N/A (D)
- Restricted Stock Unit: 2 shares at $0 (D)
- Restricted Stock Unit: 1 shares at $0 (D)

Inside Trans: Aptevo Therapeutics Inc. (APVO) by White Marvin L (President and CEO) on 2025-03-02
- Common Stock: 8 shares at $N/A (D)
- Common Stock: 6 shares at $N/A (D)
- Restricted Stock Unit: 8 shares at $0 (D)
- Restricted Stock Unit: 6 shares at $0 (D)

Inside Trans: Aptevo Therapeutics Inc. (APVO) by Lamothe Jeffrey G. (EVP, COO) on 2025-03-02
- Common Stock: 3 shares at $N/A (D)
- Common Stock: 2 shares at $N/A (D)
- Restricted Stock Unit: 3 shares at $0 (D)
- Restricted Stock Unit: 2 shares at $0 (D)

Inside Trans: Aptevo Therapeutics Inc. (APVO) by Kwon SoYoung (SVP, GC, BD & Corp Affairs) on 2025-03-02
- Common Stock: 2 shares at $N/A (D)
- Common Stock: 2 shares at $N/A (D)
- Restricted Stock Unit: 2 shares at $0 (D)
- Restricted Stock Unit: 2 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: {'value': -23721000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.98
Average Volume: 879440.13
30-Day High: 3.09
30-Day Low: 0.9981

[Detailed Financials: Q3 2024]
- Total Assets: $15,146,000.0
- Total Liabilities: $10,726,000.0
- Total Equity: $4,420,000.0
- Current Assets: $10,012,000.0
- Current Liabilities: $5,882,000.0

[Income Statement: Q3 2024]
- Revenue: N/A
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.48

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $0

[Detailed Financials: Q2 2024]
- Total Assets: $14,921,000.0
- Total Liabilities: $10,458,000.0
- Total Equity: $4,463,000.0
- Current Assets: $9,579,000.0
- Current Liabilities: $5,419,000.0

[Income Statement: Q2 2024]
- Revenue: N/A
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -1.67

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

APVO_OUT_19 [2025-04-02 14:45:46 -0400] 676 Bytes | 167 tokens | Cum: 4961 tkns (62.01% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

APVO_IN_21 [2025-04-02 14:45:46 -0400] 126 Bytes | 29 tokens | Cum: 5065 tkns (63.31% of 8k)
==========================================================================

====================================
[2025-04-02 14:45:46] # Analysis Completed
Elapsed Time: 31.88 seconds